Printer Friendly

Synthesis, characterization, and biological activity of N'-[(Z)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-4-h-pyrazol-4ylidene)(phenyl)methyl]benzohydrazide and its Co(II), Ni(II), and Cu(II) complexes.

1. Introduction

Compounds derived from 4-acylpyrazol-5-one have continued to receive considerable attention due to their pharmaceutical importance and high biological activity [1-3]. They also enjoy a range of applications as a substructure in dye chemistry and synthesis [4]. The facile incorporation of conjugated systems with special features into the pyrazolone core leads to the formation of compounds with intense colour. Hydrazones and other Schiff bases are among the most studied 4-acylpyrazol-5-one derivatives, more so considering the fact that molecules with hydrazine moiety have been noted for their biological activity [5], especially as potential inhibitors for many enzymes [6]. The interest in the chemistry of 4-acylpyrazol-5-one Schiff bases stems from their interesting ligating ability due to the presence of multielectron rich donor atoms [7-9]. This is augmented by their tendency to exist in various tautomeric forms [10-12]. The ability of this class of compounds to form coordination compounds with a wide range of transition metals has been utilized in analytical chemistry, where they have been used as effective chelating and extracting reagents for many metal ions [13-15]. The literature is replete with studies of 4acylpyrazol-5-one Schiff bases and their metal complexes. However, the study of biological activities of this class of compounds and their metal complexes is largely restricted to studies on microorganisms. Few reports are available in the literature on the study of their anticancer properties [16, 17]. With the increasing search for nonplatinum based anticancer drugs with less side effects, and similar, or better cytotoxicity, it is imperative to investigate the possibility of the use of 4-acylpyrazolone derivatives for cancer chemotherapy. In this paper, we report synthesis and characterization of N'-[(Z)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-4-H-pyrazol-4-ylidene)(phenyl)methyl]benzohydrazide and its Co(II), Ni(II) and Cu(II) complexes, the in vitro antimicrobial activity against some bacteria and yeasts, and their antiproliferative effect on human promyelocytic leukemia cells.

2. Experimental

2.1. Chemicals and Instrumentation. All the solvents are of analytical grade and were used without further purification. 1-phenyl-3-methylpyrazol-5-one, methyl benzoate and hydrazine mono-hydrate were used as supplied by Fluka. 1-phenyl-3-methyl-4-benzoyl-pyrazol-5-one and benzoylhydrazide were synthesized in accordance with reported procedures [18,19]. Elemental analyses of C, H and N were performed using Carlo Erba Elemental analyzer EA1108. Melting points were obtained with a Fisher John melting point apparatus. Magnetic moments were done on a magnetic susceptibility balance--Sherwood Scientific Cambridge, Model No.MK-I. The molar conductance measurements of the metal complexes were done in DMF/DMSO using Innolab conductivity meter Level 1. The percentage of metal in the complexes was determined using an Agilent ICP-MS7500Ce. IR spectra were recorded on a Perkin Elmer Spectrum 100 at the University of Waikato, Hamilton, New Zealand. [sup.1]H and [sup.13]C NMR spectra were obtained from a Bruker AV 500 MHz for [sup.1]H and 125 MHz for 13 C using a 5 mm quadra nuclei probe (QNP). The X-ray crystallographic data were obtained at the University of Auckland on a Bruker SMART APEX II diffraction equipped with a CCD area detector, using MoKa radiation ([lambda] = 0.71073 [Angstrom]). The software SMART was used for the collection of data frames, for indexing reflections, and to determine lattice parameters; SAINT was used for the integration of the intensity of the reflections and for scaling [20]. SADABS was used for empirical absorption correction [21]. The structures were solved using SHELXS97, and SHELXL-97 was also used for structure refinements and reporting [22]. The structures were refined by fullmatrix least-squares based on [F.sub.o.sup.2] with anisotropic thermal parameters for non-hydrogen atoms.

2.2. Synthesis of N'-[(Z)-(3-Methyl-5-oxo-1-phenyl-1,5-dihydro-4-H-pyrazol-4- ylidene)(phenyl)methyl] Benzohydrazide ([HL.sup.1]). Synthesis and crystallization of [HL.sup.1] was done by a modification of literature procedure [23] as follows.

A solution of 4-benzoyl-3-methyl-1-phenylpyrazol-5-one (2.78 g; 0.01 mol) in 30 mL ethanol was mixed with a solution of benzoyl hydrazide (1.36 g; 0.01 mol) in ethanol (20 mL). The mixture refluxed for 2 h and cooled (Figure 1). The yellow precipitate formed was isolated by gravity filtration and recrystallized from ethanol. Crystals suitable for X-ray crystallographic analysis were obtained by slow dissolution of [HL.sup.1] in ethanol by warming and addition of few drops of dimethyl formamide (DMF), followed by slow evaporation of the solution at room temperature for 1 week.

2.3. Synthesis of Ni(II), Cu(II) and Co(II) Metal Complexes of HL1. To an ethanolic solution (20 mL) of N'-[(Z)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)(phenyl) methyl]benzohydrazide (0.43 g, 0.001 mol), ethanolic solution (10 mL) of the metal chloride (0.001 mol) was added with constant stirring. The coloured mixture was then refluxed for 4 h. The resulting metal complex was filtered hot, washed with boiling mixture of 1:1 water/ethanol, dried under suction, and kept in vacuum over Ca[Cl.sub.2].

2.4. Microorganisms and Condition for Cultivation. Fifteen bacteria and five yeast cultures were used in the study. Ten bacterial strains and two yeast strains were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). Other microorganism strains were obtained from Adnan Menderes University Faculty of Medicine. The Gram-negative (G-) were Escherichia coli ATCC 25922, Salmonella typhimurium ATCC 14028, Proteus sp., Serratia marcescens, and Enterobacter sp. and the Gram-positive (G+) were Micrococcus luteus ATCC 9341, Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, Bacillus cereus ATCC 11778, Bacillus subtilis ATCC 6633, Bacillus thuringiensis, Enterococcus faecalis ATCC 29212, Enterococcus faecalis ATCC 51299, Streptococcus pneumoniae ATCC 49617, and Listeria monocytogenes. Also, yeast strains such as Candida utilis, Candida albicans ATCC 90028, Candida glabrata, Candida tropicalis, and Saccharomyces cerevisiae ATCC 9763 were used. Escherichia coli ATCC 25922, Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC 12228, Salmonella typhimurium ATCC 14028, Listeria monocytogenes, Proteus sp., Serratia marcescens, and Enterobacter sp. were cultured in nutrient broth (NB) (Merck) at 37[degrees]C; Streptococcus pneumoniae ATCC 49617, Enterococcus faecalis ATCC 29212, and Enterococcus faecalis ATCC 51299 were cultured in brain heart infusion broth (BHIB) (Merck) at 37[degrees]C for 24 h.; Micrococcus luteus ATCC 9341, Bacillus cereus ATCC 11778, Bacillus subtilis ATCC 6633, and Bacillus thuringiensis were cultured in nutrient broth (NB) (Merck) at 30[degrees]C; Candida utilis, Candida albicans ATCC 90028, Candida glabrata, Candida tropicalis, and Saccharomyces cerevisiae ATCC 9763 were cultured in malt extract broth (MEB) (Merck, USA) at 30[degrees] C for 24 h.

2.5. Antimicrobial Assay. The antimicrobial activities of all the synthesized compounds were determined by the disc diffusion method [24, 25], and the minimum inhibitory concentration (MIC) was obtained by broth dilution method [25].

2.6. Disc Diffusion Method. The standard method of Antimicrobial Disc Susceptibility Tests reported by the National Committee for Clinical Laboratory Standards [25] was used. Fresh stock solutions (1000 [micro]g x [mL.sup.-1]) of all the synthesized compounds were prepared in DMSO. The inoculum suspensions of the tested bacteria and yeasts were prepared from the broth cultures (18-24 h) and the turbidity equivalent adjusted to 0.5 McFarland standard tube to give a concentration of 1 x [10.sup.8] bacterial cells and 1 x [10.sup.6] yeast cells/mL. To test the antimicrobial activity of all the synthesized compounds, a Mueller Hinton Agar (MHA) plate was inoculated with 0.1 mL broth culture of bacteria or yeast. Then a hole of 6 mm in diameter and depth was made on top with a sterile stick and filled with 50 [micro]L of synthesized compounds. Plates inoculated with E. coli ATCC 25922, S. typhimurium ATCC 14028, S. aureus ATCC 25923, S. epidermidis ATCC 12228, E. faecalis ATCC 29212, Enterococcus faecalis ATCC 51299, S. pneumoniae ATCC 49617, Listeria monocytogenes, Proteus sp., S. marcescens, and Enterobacter sp. were incubated at 37[degrees]Cfor 24 h, while those with M. luteus ATCC 9341, Bacillus subtilis ATCC 6633, B. cereus ATCC 11778, B. thuringiensis, S. cerevisiae ATCC 9763, C. albicans ATCC 90028, C. glabrata, C. utilis, and C. tropicalis were incubated at 30[degrees]C for 24 h. At the end of incubation time, the diameters of the inhibition zones formed on the MHA were evaluated in millimeters. Disc of chloramphenicol (C30), gentamicin (CN10), tetracycline (TE30), erythromycin (E15), ampicillin (AMP10), and nystatin (NS100) were used as positive controls. The measured inhibition zones of the study compounds were compared with those of the reference discs.

2.7. Minimum Inhibitory Concentration (MIC). Minimum inhibitory concentration (MIC) was determined by reported method [25]. The study bacteria were inoculated in nutrient broth and incubated at 30-37[degrees]C for 24 hr while the yeasts were inoculated in Malt Extract Broth and incubated at 30[degrees]C for 48 h. The inoculums were adjusted according to 0.5 McFarland standard tube. Initially, 100 [micro]L of Mueller Hinton Broth (MHB) was placed in each well. After, the compounds were dissolved in DMSO (2 mg [mL.sup.-1]) and transferred into the first well. Two fold serial dilution of the compounds were carried out to determine the MIC, within the concentration range 256 to 0.125 [micro]g [mL.sup.-1]. Cultures were grown at 30-37[degrees]C (18-20 h) and the final inoculum was approximately [10.sup.6] cfu [mL.sup.-1]. The lowest concentration of the study compounds that resulted in complete inhibition of the microorganisms was represented as MIC ([micro]g [mL.sup.-1]). Similar procedures were done on positive controls, streptomycin (I. E. Ulagay). In each case, the test was performed in triplicate and the results were expressed as means.

2.8. Cell Antiproliferation Test. HL-60 promyelocytic leukaemia cells were purchased from ATCC. Cells were grown in RPMI-1640 medium supplemented with 10% heat inactivated fetal calf serum, 1% L-glutamine, and 1% penicillin/C[O.sub.2].

All media and supplements were obtained from Life Technologies. HL 60 cells were seeded in T-25 tissue culture flasks at a concentration of 1 x [10.sup.5]/mL and incubated with increasing concentrations (5,10, 20, and 40 [micro]M) of the study compounds. Cell counts and [IC.sub.50] values were determined at 24 and 72 h using a Thoma slide. Experiments were done in triplicate. The percentage of cell divisions compared to the untreated control was calculated as follows:

[(C72 h + drug - C24 h + drug)/ (C72 h - drug - C24 h - drug)] x 100 (1) = % cell division,

where C72 h + study compound is the cell number after 72 h of treatment with study compound, C24 h + compound is the cell number after 23 h of treatment with study compound, C72 h - compound is the cell number after 72 h without treatment with compound, and C24 h - compound is the cell number after 24 h without treatment with compound.

3. Results and Discussion

3.1. X-Ray Crystal Structure of [HL.sup.1]. The crystal structure of [HL.sup.1] has been reported in literature [23] but was redetermined to investigate if the new method of crystal isolation could affect the R-factor which was earlier reported as 0.0542 [23], and control the intramolecular rearrangement of the molecule from structure (4) to any of the other tautomers, see Figure 1. The data and structure refinement parameter details are given in Table 2. The crystal structure of HL1 was solved by direct method. The nitrogen and oxygen atoms were located followed by other atoms in subsequent refinements. All nonhydrogen atoms were refined as anisotropic. The Xray crystal structures and atom numbering schemes of HL1 are as shown in Figure 2. The selected bond lengths and angles are shown in Table 1. The crystal data and structure refinement details are presented in Table 2. The compound is a nonplanar molecule. The measured angle between the pyrazolone ring plane C(18) C(17) C(16) N(3) and C(6) C(1) C(5) plane is 71.4[degrees]. In addition the angle between C(8) N(2) N(1) and C(6) C(7) N(1) planes is 33.6[degrees]. The phenacyl group adopts a gauche conformation about the N-N vector. The angle between the phenacyl C(13) C(14) C(9) and N(2) C(14) C(8) planes is 29.9[degrees]. The hydrazino nitrogen atoms adopted the trans-conformation which is more preferred when not in a ring system [26, 27]. The bond length of hydrazino (>N-N<) nitrogen atoms 1.3820(9) [Angstrom] the carbonyl (>C=O) group 1.2396(9) [Angstrom] is in agreement with literature reports [23, 28]. The ring carbon-oxygen O(2)-C(18) bond length 1.2655(9) [Angstrom] is longer but in good agreement with earlier reports on the pyrazolone ring carbonyl group [23, 29]. The molecular structure of the compound indicated intermolecular hydrogen bonding between the hydrogen atom on N(2) and the O(2) forming a non planar seven membered ring system. Intramolecular hydrogen bonding is also observed in the molecule as shown in the crystal packing motif in Figure 3.

3.2. Analytical and Physical Data. All the metal complexes are colored and soluble in polar solvents (dimethyl sulfoxide, dimethyl formamide, and anhydrous ethanol) but insoluble in solvents such as hexane, pentane, tetrahydrofuran and carbon tetrachloride. Analytical and physical data of all the study compounds are shown in Table 3. The complexes are nonelectrolytes in DMSO, as evident from the molar conductivity values which range from ~9 to 13 [Ohm.sup.-1] [cm.sup.2] [mol.sup.-1] [30-32].

3.3. FT-Infrared Spectra. The relevant stretching frequencies are tabulated in Table 4. The absorption bands in the region ~3000-3280 [cm.sup.-1] in the spectral of [HL.sup.1] and the metal complexes were assigned to NH stretching vibrations. Two strong [nu](C=O) bands are observable in the keto-amine form of [HL.sup.1], one assignable to [nu](C=O) of the lateral chain comprising the hydrazide moiety and the other to the [nu](C=O) of pyrazolone ring [33-35]. These strong vibrational bands ([cm.sup.-1]) were observed at 1645 and 1596, respectively. The [nu](C=O) band assigned to the hydrazide moiety shifted to lower frequencies in the metal complexes, suggesting that the carbonyl oxygen was involved in coordination to the metal ions [36-38]. Bands in the region of 1566-1570 [cm.sup.-1] have been assigned to imino [nu](C=N) in all the metal complexes. The bands in the region of 1437-1440 [cm.sup.-1] in the metal complexes have been assigned to [nu](C-O) [33,39] resulting from enolization and deprotonation before coordination [14, 40].

The bands in the region ~1025-1120 [cm.sup.-1] in the ligand and the metal complexes have been assigned to [nu](N-N). Bands in the range ~510-520 [cm.sup.-1] in the metal complexes were assigned to [nu] (M-O) while bands in the range ~420480 [cm.sup.-1] were assigned to [nu] (M-N) [41-43]. [nu]O-H of water of crystallization was observed in the region ~3370-3470 [cm.sup.-1] in the metal complexes. [HL.sup.1] reacted as the enol-imino form (Figure 1 (5)), when coordinated to metal ions in solution, coordinating via pyrazolone ring enolic (C-O), azomethine (C=N), and hydrazide side chain (C=O).

3.4. [sup.1]H and [sup.13]C NMR Spectra. The possible keto forms of HL1 are as shown in Figure 1. The X-ray structure confirmed that it crystallized in the keto-amine form (4). The conjugated system that extended from the pyrazolone ring confers extra stability on form (4). In the [sup.1]H NMR spectrum the 3-methyl protons signal was observed as singlet upfield at 2.17 ppm. The phenyl protons appeared as multiplets in the range 7268.07 ppm while the signal due to -NH was observed at 8.83 ppm. The [sup.13]C-NMR spectrum of the ligand exhibited 17 carbon signals comprising 16 [sp.sup.2] and one [sp.sup.3] (-CH3) carbons; the signal at [delta]16.06 has been assigned to carbon of the pyrazolone core side 3-methyl. Carbons of benzene rings are present at [delta] 118.47-165.18. The most deshielded carbons have been assigned relevant signals downfield. The assignments are as follows: C-1 = 127.55, C-2 = 127.42, C-3 = 129.70, C-4 = 127.42, C-5 = 127.55, C-6 = 131.43, C-7 = 138.75, C-8 = 163.64, C-9 = 130.69, C-10 = 148.27, C-11 = 132.78, C12 = 130.04, C-13 = 128.83, C-14 = 130.04, C-15 = 15.44, C-16 = 149.28, C-17 = 120.34, C-18 = 154.55, C-19 = 138.22, C-20 = 119.85, C-21 = 129.70, C-22 = 125.26, C-23 = 129.70 and C24 = 119.85 ppm (see (4) in Figure 1). All assignments were consistent with literature on related studies [44-48].

3.5. Electronic Spectra and Magnetic Studies. The significant electronic absorption bands in the spectra of the ligand and the metal complexes recorded in DMSO solution are presented in Table 5. The ligand shows high frequency-bands at 42,533, 32,786, and 29,411[cm.sup.-1] which were assigned to n [right arrow] [[pi].sup.*] and [pi] [right arrow] [[pi].sup.*] transitions [49, 50]. For a typical [d.sup.9] octahedral [Cu.sup.2+] complex the 2D free-ion term is split into two levels by the Oh symmetry and further split on distortion to [D.sub.4h] or [C.sub.4v] symmetry [51]. Three spin allowed transitions can be observed in the visible and near IR regions. In the present study the Cu(II) complex show bands at 16,354,13,424 and 22,722 [cm.sup.-1] which have been assigned to 2B1g _ 2B2g, [sup.2][B.sub.1g] [right arrow] [sup.2][A.sub.1g] and [sup.2][B.sub.1g] [right arrow] [sup.2]Eg transitions respectively [5254]. The observed magnetic moment of 1.90 B.M is suggestive of an octahedral geometry for Cu(II) complex [54]. Ni(II) with [d.sup.8] configuration in an octahedral field has a ground state of [sup.3]F, which is split into [sup.3][A.sub.2g], [sup.3][T.sub.2g], and [sup.3][T.sub.1g](F) states and the excited state designated as [sup.3][T.sub.1g](P). Three bands can be observed in the spectra. The Ni(II) complex displays three bands at 12,545, 14,174, and 23,809, [cm.sup.-1] assignable to [sup.3][A.sub.2g] [right arrow] [sup.3][T.sub.2g](F), [sup.3][A.sub.2g] [right arrow] [sup.3][T.sub.1g](F), and [sup.3][A.sub.2g] [right arrow] [sup.3][T.sub.1g](P) transitions, respectively [55]. The magnetic moment of 2.93 B.M for Ni(II) complex is an indication of its octahedral geometry. The three bands observed at 21,276, 20,408, and 10,204 [cm.sup.-1] for Co(II) complexes have been assigned to [sup.4][T.sub.1g](F) [right arrow] [sup.4][T.sub.1g](P), [sup.4][T.sub.1g](F) [right arrow] [sup.4][A.sub.2g](F) and [sup. 4][T.sub.1g](F) [right arrow] [sup.4][T.sub.2g](F) transitions, respectively [52]. The magnetic moment of 4.94 B.M and the observed electronic transitions indicate high spin octahedral geometry of the complex [56].

On the basis of microanalytical data, magnetic moments, conductivity measurements, and spectral analysis, Figure 4 has been proposed for the metal complexes.

3.6. Antimicrobial Test Results. The results of antimicrobial activities of the study compounds reported as inhibition zone diameter (mm) are showed in Table 6. The inhibition zone diameter of the reference antibiotics used on the test microorganisims are presented in Table A which can be found in Supplementary Material available online at http:// The MIC values which suggested that some of the studied compounds exhibited appreciable antimicrobial activity are showed in Table 7. The ligand, Co(II) and Cu(II) complexes showed appreciable activities against some pathogen bacteria, while the Ni(II) complex did not show any antimicrobial activity. The ligand (HL1) showed significant antimicrobial activity against four Gram- positive bacteria Micrococcus luteus ATCC 9341, Staphylococcus aureus ATCC 25923, Bacillus cereus ATCC 11778, and Bacillus subtilis ATCC 6633; the Co complex showed antimicrobial activity against two Gram-positive bacteria Bacillus cereus ATCC 11778 and Bacillus subtilis ATCC 6633. Cu(II) complex exhibited antimicrobial activity against three Gram-positive bacteria Micrococcus luteus ATCC 9341, Staphylococcus aureus ATCC 25923, and Bacillus cereus ATCC 11778. However, none of the study compounds exhibited antimicrobial activity against tested Gram-negative bacteria and yeasts. Gram-negative bacteria are noted for the protective lipopolysaccharide (LPS) in the outer membrane of their cell walls, which protects the sensitive inner membrane and the cell wall from drugs and dyes [57]. This protective lipopolysaccharide is absent in Gram-positive bacteria. In order for these compounds to exert bacteriostatic or bactericidal actions, they must access intracellular targets [58, 59]. Therefore in Gram-negative bacteria, these compounds must cross the outer membrane, a substantial permeability barrier and thus a major determinant of antimicrobial resistance in these bacteria [59]. The observed results of the antimicrobial tests suggest that the compounds were not able to permeate the protective outer membrane of the Gram negative bacteria to the extent of having antimicrobial effects. The observed better antimicrobial action exhibited by the ligand may be ascribed to the formation of hydrogen bonds with the active centre of cell constituents, resulting in interference with the normal function of the cell [60]. On coordination, the site for hydrogen bonding is minimized in the resultant metal complexes.

MICs were measured for the compounds that showed appreciable growth inhibition zones; the study was restricted to microorganisms that were affected by the compounds. From the results of MIC tests shown in Table 7, it can be seen that MIC of selected compounds against bacterial pathogens varied from 4 to 128 [micro]g [mL.sup.-1]. The lowest MICs were observed for [HL.sup.1] (4-8 [micro]g [mL.sup.-1]) against the four tested microorganisms. Low MICs were also recorded for Cu complex (Staphylococcus aureus ATCC 25923) and Co complex (Bacillus cereus ATCC 11778). The results suggest that the compounds showed good antimicrobial activity against these organisms.

3.7. Results of Cell Proliferation Test. HL-60 (human promyelocytic leukemia cells) cell line is a leukemic cell line that has been used for laboratory research. The HL-60 cultured cell line provides a continuous source of human cells for studying the molecular events of myeloid differentiation and the effects of physiologic, pharmacologic, and virologic processes. The results of antiproliferative activities of investigated compounds against human cancer (HL-60) cell line are presented in Table 8. The results indicated that [HL.sup.1] and its Cu(II) complex exhibit cytotoxic effects at the lowest tested concentration with [IC.sub.50] value between ~3 and 5 [micro]M while the Co(II) and Ni(II) complexes exhibit better cytotoxic effects with [IC.sub.50] value ~2-3 [micro]M. Figure 5 shows effects of different concentrations of tested compounds on HL-60 cell line. It is evident from Figure 5 that all the compounds (at <5-40 [micro]M) were able to inhibit the proliferation of more than 50% of the HL-60 cell. The tested compounds can be described as potent anticancer agents due to their considerably high antiproliferative effects. This is consistent with documented facts by the US NCI screening program, that if the [IC.sub.50] value (following the incubation of a compound and cell lines between 48 and 72 h) is less than 10 [micro]M, the compound is considered to have in vitro cytotoxic activity [61].

4. Conclusions

A 4-acylpyrazolone hydrazone and some of its metal complexes have been synthesized and characterized. The crystal and spectra data showed that the ligand crystallized in the keto-amine form and coordinated as a monoanionic tridentate ONO donor ligand. Physicochemical and spectral data show that the metal to ligand ratio is 1 :2 in the Ni(II), Cu(II), and Co(II) complexes. The electronic data and magnetic moments are in favour of octahedral geometry for Ni(II), Cu(II), and Co(II) complexes. The compounds exhibited better antimicrobial activity against Gram-positive bacterial strains studied. The cytotoxicity test results showed that the compounds are potential anticancer agents.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.


The authors are thankful to the Nigerian Education Trust Fund (ETF) and the University of Nigeria, Nsukka, for research grant offered to Jonnie N. Asegbeloyin for a research visit to Adnan Menderes University, Turkey, Zeynep Tasci of Department of Inorganic Chemistry, Ege University, Izmir, for magnetic moment measurements, and Dr. Tania Groutso (University of Auckland) for collection of the X-ray data sets.


[1] Y. Zhang, L. Zhang, L. Liu et al., "Anticancer activity, structure, and theoretical calculation of N-(1-phenyl-3-methyl-4-propylpyrazolone-5)-salicylidene hydrazone and its copper(II) complex," Inorganica Chimica Acta, vol. 363, no. 2, pp. 289-293, 2010.

[2] J. D. Patel and P J. Shah, "Synthesis, characterization and chelating properties of 4-butyrylsemicarbazone-1-phenyl-3-methyl-2-pyrazolin-5-one," E-Journal of Chemistry, vol. 7, no. 2, pp. 357362, 2010.

[3] A. S. Thakar, K. K. Singh, K. T Joshi, A. M. Pancholi, and K. S. Pandya, "Synthesis, characterization and antibacterial activity of schiff bases and their metal complexes derived from 4-Acyl-1-phenyl-3-methyl-2-pyrazolin-5-ones and 2-Amino-4(4'methylphenyl)thiazole," E-Journal of Chemistry, vol. 7, no. 4, pp. 1396-1406, 2010.

[4] J. Wang, L. Liu, G. Liu, J. Guo, and D. Jia, "Three novel photoisomeric compounds of the 4-acyl pyrazolone derivants: crystal structures and substituent effects on photo-isomerism in solid state," Science in China B: Chemistry, vol. 51, no. 7, pp. 661-668, 2008.

[5] K.-K. Bedia, O. Elcin, U. Seda et al., "Synthesis and characterization of novel hydrazide-hydrazones and the study of their structure-antituberculosis activity," European Journal of Medicinal Chemistry, vol. 41, no. 11, pp. 1253-1261, 2006.

[6] H. Adams, D. E. Fenton, G. Minardi, E. Mura, A. M. Pistuddi, and C. Solinas, "A coordination polymer derived from the copper(II) complex of a bis-(salicylhydrazone) derived from iminodiacetic acid diethyl ester," Inorganic Chemistry Communications, vol. 3, no. 1, pp. 24-28, 2000.

[7] X. Hu, L. Zhang, L. Liu, G. Liu, D. Jia, and G. Xu, "Synthesis and structural characterization of three hydrogen-bonding connected supramolecular complexes of nickel, zinc and copper with 1,3-diphenyl-4-(salicylidene hydrazide)-acetyl-pyrazolone-5 and 2,2'-bipyridine," Inorganica Chimica Acta, vol. 359, no. 2, pp. 633-641, 2006.

[8] D. S. Raj, N. J. Parmar, and J. R. Shah, "Synthesis and physicochemical studies on nickel(II) chelates of some tetradentate bisketimino derivatives of 4-acyl-2-pyrazolin-5-ones," Synthesis and Reactivity in Inorganic and Metal-Organic Chemistry, vol. 34, no. 4, pp. 697-711, 2004.

[9] L. Zhang, L. Liu, D. Jia, G. Xu, and K. Yu, "Synthesis and structures of dinuclear copper(II) complex and [mu]-phenolatotetrazinc(II) complex with 1,3-diphenyl-4-(salicylidene hydrazone)phenylethylene-pyrazolone-5," Inorganic Chemistry Communications, vol. 7, no. 12, pp. 1306-1310, 2004.

[10] L. Zhang, L. Liu, G. Xu, and D. Jia, "Syntheses, crystal structures and fluorescence properties of Zn(II) complexes with pyrazolone derivatives," Journal of Chemical Crystallography, vol. 38, no. 11, pp. 837-843, 2008.

[11] N. J. Parmar and S. B. Teraiya, "Cobalt(II) and nickel(II) chelates of some 5-pyrazolone-based, Schiff-base ligands," Journal of Coordination Chemistry, vol. 62, no. 14, pp. 2388-2398, 2009.

[12] K. B. Vyas, K. S. Nimavat, G. R. Jani, and M. V Hathi, "Synthesis and antimicrobial activity of coumarin derivatives metal complexes: an in vitro evaluation," Orbital, vol. 1, no. 2, pp. 183192, 2009.

[13] N. Burham, S. M. Abdel-Azeem, and M. F. El-Shahat, "Removal of Pb and Cd from aqueous media and fish liver using novel polyurethane foam functionalized with pyrazolone as a new metal ion collector," Central European Journal of Chemistry, vol. 7, no. 3, pp. 576-585, 2009.

[14] N. J. Parmar, H. A. Barad, B. R. Pansuriya, and R. A. Patel, "Chelation and extraction of copper(II) with 5-pyrazolonebased Schiff bases," Journal of Coordination Chemistry, vol. 64, no. 4, pp. 688-698, 2011.

[15] M. F. Iskander, L. El Sayed, A. F. M. Hefny, and S. E. Zayan, "Coordination compounds of hydrazine derivatives with transition metals-XII Nickel(II) and copper(II) chelates of bis(nsalicylidene)dicarboxylic acid dihydrazides," Journal of Inorganic and Nuclear Chemistry, vol. 38, no. 12, pp. 2209-2216,1976.

[16] X.-H. Wang, D.-Z. Jia, Y.-J. Lianget al., "Lgf-YL-9 induces apoptosis in human epidermoid carcinoma KB cells and multidrug resistant KBv200 cells via reactive oxygen species-independent mitochondrial pathway," Cancer Letters, vol. 249, no. 2, pp. 256270, 2007.

[17] M. F. Brana, A. Gradillas, A. G. Ovalles et al., "Synthesis and biological activity of N,N-dialkylaminoalkyl-substituted bisindolyl and diphenyl pyrazolone derivatives," Bioorganic & Medicinal Chemistry, vol. 14, no. 1, pp. 9-16, 2006.

[18] S. B. Jensen, "The synthesis of 1-phenyl-3-methyl-4-acyl-pyrazolone-5," Acta Chemica Scandinavian, vol. 13, pp. 1668-1670, 1959.

[19] L. N. Volovelskii and G. V. Knorozova, "Synthesis of derivatives of the androstane series III. Dihydrazones of 2-hydroxymethylenedihydrotestosterone tosterone and 2-hydroxymethylene-17a-methyldihydrotestosterone," Zhurnal Obshchei Khimii, vol. 34, no. 1, pp. 343-347,1964.

[20] S. Saint, Software Reference Manuals, Siemens Energy & Automation Inc., Analytical Instrumentation, Madison, Wis, USA, 2001.

[21] G. M. Sheldrick, SADABS, A Software for Empirical Adsorption Correction, University of Gottingen, Gottingen, Germany, 1997.

[22] G. M. Sheldrick, SHELXL-97 Programs for the Solution and Refinement of Crystal Structures, University of Gottingen, Gottingen, Germany, 1997.

[23] S. Sawusch, N. Jager, U. Schilde, and E. Uhlemann, "Ligand exchange reactions of ReO[Cl.sub.3] [(P[Ph.sub.3]).sub.2] with tridentate diacidic ligands with the donor set O [??] N [??] O(N): molecular and electronic structures of the resulting oxo-rhenium(V) complexes," Structural Chemistry, vol. 10, no. 2, pp. 105-119,1999.

[24] C. H. Collins, P. M. Lyre, and J. M. Grange, Microbiological Methods, Butterworths, London, UK, 1987.

[25] National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Disk Susceptibility Tests, Approved Standard, National Committee for Clinical Laboratory Standards (NCCLS) Publication, Villanova, Pa, USA, 1993.

[26] R. Shintani, "The crystal and molecular structure of anhydrous diacetylhydrazine(-NHCOCH3)2," Acta Crystallographica, vol. 30, pp. 609-618, 1960.

[27] T. Ottersen and J. Almlof, "The electron density distribution in hexahydro-3,6-pyridazinedione," Acta Chemica Scandinavica, vol. 32, pp. 219-224, 1978.

[28] L. Zhang, G.-C. Xu, L. Liu, G.-F. Liu, and D. Jia, "Synthesis, characterization and crystal structure of 1-phenyl-3-methyl-4- (salicylidene hydrazide)-phenylethylene-pyrazolone-5," Journal of Chemical Crystallography, vol. 38, no. 2, pp. 151-155, 2008.

[29] V. I. Sokol, S. B. Strashnova, O. V. Kovalchukova et al., "Synthesis, spectral characteristics, and the crystal and molecular structures of 2,3-dimethyl-1-phenyl-4-(N-phthalimido)pyrazolone-5," Crystallography Reports, vol. 53, no. 6, pp. 998-1002, 2008.

[30] R. C. Aggarwal and T. R. Rao, "Synthesis and structural studies of some first row transition metal complexes of isonicotinic acid hydrazide," Current Science, vol. 46, no. 18, pp. 625-628,1977.

[31] B. S. Garg and L. Kapur, "Spectral characterization of bimetallic complexes of monoacetylferrocenethiosemicarbazone (MAFTSC) with Co(II) salts," Inorganica Chimica Acta, vol. 173, no. 2, pp. 223-227, 1990.

[32] R. Sreekala and K. K. M. Yusuf, "Synthesis, characterization and cytotoxity of new complexes of cobalt(III), nickel(II) and copper(II) with quinoxaline-2-carboxaldehyde thiosemicarbazone," Synthesis and Reactivity in Inorganic and MetalOrganic Chemistry, vol. 24, no. 10, pp. 1773-1788, 1994.

[33] G. C. Xu, L. Zhang, L. Liu, G. Liu, and D. Z. Jia, "Syntheses, characterization and crystal structures of mixed-ligand Cu(II), Ni(II) and Mn(II) complexes of N-(1-phenyl-3-methyl-4propenylidene-5-pyrazolone)-salicylidene hydrazide containing ethanol or pyridine as a co-ligand," Polyhedron, vol. 27, no. 1, pp. 12-24, 2008.

[34] L. Zhang, L. Liu, D. Jia, and K. Yu, "Synthesis and crystal structure of mixed-ligand Ni(II) complex of N-(1-phenyl-3-methyl-4-benzylidene-5-pyrazolone) p-nitrobezoylhydrazide and pyridine," Structural Chemistry, vol. 15, no. 4, pp. 327-331, 2004.

[35] N. Raman, A. Kulandaisamy, A. Shunmugasundaram, and K. Jeyasubramanian, "Synthesis, spectral, redox and antimicrobial activities of Schiff base complexes derived from 1-phenyl-2,3dimethyl-4-aminopyrazol-5-one and acetoacetanilide," Transition Metal Chemistry, vol. 26, no. 1-2, pp. 131-135, 2001.

[36] R. Rajavel, M. S. Vadivu, and C. Anitha, "Synthesis, physical characterization and biological activity of some schiff base complexes," E-Journal of Chemistry, vol. 5, no. 3, pp. 620-626, 2008.

[37] M. Thankamony and K. Mohanan, "Synthesis, spectral studies, thermal decomposition kinetics, reactivity and antibacterial activity of some lanthanide(III) nitrate complexes of 2(N-indole-2-one)amino-3-carboxyethyl-4,5,6,7-tetrahydrob- enzo[b]thiophene," Indian Journal of Chemistry A: Inorganic, Physical, Theoretical and Analytical Chemistry, vol. 46, no. 2, pp. 247-251, 2007.

[38] N. R. Pramanik, S. Ghosh, T. K. Raychaudhuri, S. Chaudhuri, M. G. B. Drew, and S. S. Mandal, "Chemical, electrochemical and structural studies of some cis-dioxomolybdenum (VI) complexes of two tridentate ONS chelating ligands," Journal of Coordination Chemistry, vol. 60, no. 20, pp. 2177-2190, 2007

[39] S. Belaid, A. Landreau, S. Djebbar, O. Benali-Ba'itich, M. A. Khan, and G. Bouet, "Synthesis, characterisation and antifungal activity of a series of Cobalt(II) and Nickel(II) complexes with ligands derived from reduced N, N'-o-Phenylenebis(Salicylideneimine)," Transition Metal Chemistry, vol. 33, no. 4, pp. 511-516, 2008.

[40] R. J. Yadav, K. M. Vyas, and R. N. Jadeja, "Synthesis and spectral characterization of Cu(II) complexes of some thio-Schiff bases of acyl pyrazolone analogues," Journal of Coordination Chemistry, vol. 63, no. 10, pp. 1820-1831, 2010.

[41] P. B. Sreeja and M. R. P. Kurup, "Synthesis and spectral characterization of ternary complexes of oxovanadium(IV) containing some acid hydrazones and 2,2'-bipyridine," Spectrochimica Acta A: Molecular and Biomolecular Spectroscopy, vol. 61, no. 1-2, pp. 331-336, 2005.

[42] A. P. Mishra and L. R. Pandey, "Synthesis, structure and reactivity of oxovanadium(IV) Schiff base complexes," Indian Journal of Chemistry A, vol. 44, no. 9, pp. 1800-1805, 2005.

[43] K. Nakamoto, Infrared and Raman Spectra of Inorganic and Coordination Compounds. Part A and Part B, John Wiley & Sons, NewYork, NY, USA, 1998.

[44] E. C. Okafor, "A [sup.1]H and [sup.13]C-NMR spectral study of some 4-acyl-3-methyl-1-phenylpyrazol-5-ones in chloroform," Spectrochimica Acta A, vol. 40, no. 5, pp. 397-401,1984.

[45] A. K. Rana, N. R. Parekh, H. R. Dabhi, and S. S. Nadkarni, "Novel synthesis and characterization of thiosemicarbazone compounds containing 4-acyl-2-pyrazolin-5-ones," E-Journal of Chemistry, vol. 6, no. 3, pp. 747-752, 2009.

[46] E. C. Okafor, "The metal complexes of heterocyclic [beta]-diketones and their derivatives-VII. The synthesis, structure and i.r. spectral studies of 1-phenyl-3-methyl-4-trifluoroacetyl-pyrazolone-5 (HPMTFP) and its divalent metal complexes," Spectrochimica Acta A: Molecular Spectroscopy, vol. 37, no. 11, pp. 951-955,1981.

[47] E. C. Okafor, "The metal complexes of heterocyclic [beta]-diketones and their derivatives-VII. The synthesis, structure and i.r. spectral studies of 1-phenyl-3-methyl-4-trifluoroacetyl-pyrazolone-5 (HPMTFP) and its divalent metal complexes," Spectrochimica Acta A, vol. 37, no. 11, pp. 951-955,1981.

[48] H. W. Dudley and F. Ian, Spectroscopic Methods in Organic Chemistry, McGraw-Hill, London, UK, 4th edition, 1989.

[49] A. S. Munde, A. N. Jagdale, S. M. Jadhav, and T. K. Chondhekar, "Synthesis and characterization of some transition metal complexes of unsymmetrical tetradentate Schiff base ligand," Journal of the Korean Chemical Society, vol. 53, no. 4, pp. 407414, 2009.

[50] G. M. Gehad, M. M. Omar, and A. M. Hindy, "Metal complexes of Schiff bases: preparation, characterization, and biological activity," Turkish Journal of Chemistry, vol. 30, no. 3, pp. 361382, 2006.

[51] G. L. Miessler and D. A. Tarr, Inorganic Chemistry, Prentice Hall, Upper Saddle River, NJ, USA, 2nd edition, 1999.

[52] S. Chandra and A. Kumar, "Spectral studies on Co(II), Ni(II) and Cu(II) complexes with thiosemicarbazone (L1) and semicarbazone (L2) derived from 2-acetyl furan," Spectrochimica Acta A, vol. 66, no. 4-5, pp. 1347-1351, 2007

[53] U. L. Kala, S. Suma, M. R. P. Kurup, S. Krishnan, and R. P. John, "Synthesis, spectral characterization and crystal structure of copper(II) complexes of 2-hydroxyacetophenone-N(4)-phenyl semicarbazone," Polyhedron, vol. 26, no. 7, pp. 1427-1435, 2007

[54] C. J. Ballhauseu, An Introduction to Ligand Field Theory, McGraw Hill, New York, NY, USA, 1962.

[55] J. D. Lee, Concise Inorganic Chemistry, Blackwell Science, Oxford, UK, 5th edition, 1996.

[56] N. Raman, S. Ravichandran, and C. Thangaraja, "Copper(II), cobalt(II), nickel(II) and zinc(II) complexes of Schiff base derived from benzil-2,4-dinitrophenylhydrazone with aniline," Journal of Chemical Sciences, vol. 116, no. 4, pp. 215-219, 2004.

[57] H. Nikaido, "Prevention of drug access to bacterial targets: permeability barriers and active efflux," Science, vol. 264, no. 5157, pp. 382-388,1994.

[58] K. Poole, "Mechanisms of bacterial biocide and antibiotic resistance," Journal of Applied Microbiology Symposium Supplement, vol. 92, no. 1, pp. 55-64, 2002.

[59] K. Todar, "Bacterial resistance to antibiotics," Todar's online textbook of bacteriology, 2011.

[60] N. Dharmaraj, P. Viswanathamurthi, and K. Natarajan, "Ruthenium(II) complexes containing bidentate Schiff bases and their antifungal activity," Transition Metal Chemistry, vol. 26, no. 1-2, pp. 105-109, 2001.

[61] V. Kuete, B. Ngameni, B. Wiench et al., "Cytotoxicity and mode of action of four naturally occuring flavonoids from the genus dorstenia: gancaonin Q, 4-hydroxylonchocarpin, 6-prenylapigenin, and 6,8-diprenyleriodictyol," Planta Medica, vol. 77, no. 18, pp. 1984-1989, 2011.

Jonnie N. Asegbeloyin, (1) Oguejiofo T. Ujam, (1) Emmanuel C. Okafor, (1) Ilknur Babahan, (2) Esin Poyrazoglu Coban, (3) Ali Ozmen, (3) Halil Biyik (3)

(1) Department of Pure and Industrial Chemistry, University of Nigeria, Enugu State, Nsukka 410001, Enugu State, Nigeria

(2) Department of Chemistry, Adnan Menderes University, 09010 Aydin, Turkey

(3) Department of Biology, Adnan Menderes University, 09010 Aydin, Turkey

Correspondence should be addressed to Jonnie N. Asegbeloyin;

Received 3 April 2014; Accepted 10 June 2014; Published 15 September 2014

Academic Editor: Nick Katsaros

TABLE 1: Selected bond lengths ([Angstrom]) and bond angles
([degrees]) for [HL.sup.1] (estimated standard deviations are in

                   Bond lengths and atomic
                     distances ([Angstrom])

O(1)-C(8)    1.2396(9)    N(3)-C(16)   1.3097(11)
O(2)-C(18)   1.2655(9)    N(3)-N(4)    1.4003(10)
N(1)-C(7)    1.3299(10)   N(4)-C(18)   1.3766(10)
N(1)-N(2)    1.3820(9)    N(4)-C(19)   1.4140(10)
N(2)-C(8)    1.3487(10)   C(1)-C(2)    1.3899(13)

                   Bond angles ([degrees])

C(7)-N(1)-N(2)     123.33(7)   N(1)-C(7)-C(17)   125.71(7)
C(8)-N(2)-N(1)     119.20(7)   N(1)-C(7)-C(6)    112.99(7)
C(16)-N(3)-N(4)    106.36(6)   O(1)-C(8)-N(2)    122.97(7)
C(18)-N(4)-N(3)    112.14(6)   O(1)-C(8)-C(14)   122.98(7)
C(18)-N(4)-C(19)   129.16(7)   N(2)-C(8)-C(14)   114.05(7)
N(3)-N(4)-C(19)    118.67(6)   O(2)-C(18)-N(4)   124.30(7)

TABLE 2: Crystal data and structure refinement details for HL1.

Identification code                    [HL.sup.1]

Formula                                [C.sub.24][H.sub.20]
Formula weight                         396.44
Temperature (K)                        109(2)
Wavelength (A)                         0.71073
Crystal system                         Triclinic
Space group                            P-1
a/[Angstrom]                           9.0895(2)
b/[Angstrom]                           10.9699(3)
c/[Angstrom]                           11.0637(3)
[alpha]/[degrees]                      89.5410(10)
[beta]/[degrees]                       78.6940(10)
[gamma]/[degrees]                      66.0660(10)
Volume ([[Angstrom].sup.3])            985.59(4)
Z                                      2
Calculated density (Mg/[m.sup.3])      1.336
Absorption coefficient ([mm.sup.-1])   0.088
F(000)                                 416
Crystal size ([mm.sup.3])              0.70 x 0.49 x 0.28 mm
Theta range for data collection        2.50 to 34.28 [degrees]
Limiting indices                       -14 [less than or equal to] h
                                       [less than or equal to] 13,-17
                                       [less than or equal to] k
                                       [less than or equal to] 16,
                                       -16 [less than or equal to] l
                                       [less than or equal to] 17
Reflections collected/unique           29726/7289 [R(int) = 0.0274]
Completeness to theta                  2750[degrees] 100.0%
Absorption correction                  Multiscan
Max. and min. transmission             0.9759 and 0.9412
Refinement method                      Full-matrix least-squares on
Data/restraints/parameters             7289/0/278
Goodness of fit on [F.sup.2]           1.028
Final R indices [I > 2[sigma](I)]      [R.sub.1] = 0.0439,
                                       w[R.sub.2] = 0.1199
R indices (all data)                   [R.sub.1] = 0.0535,
                                       w[R.sub.2] = 0.1282
Largest diff. peak and hole            0.440 and -0.289 e [A.sup.-3]

TABLE 3: Elemental analysis and physical data of the ligand and

Compound            Colour   MF

[HL.sup.1]          Yellow   [C.sub.24][H.sub.20]
Co[L.sup.1.sub.2]   Yellow   [C.sub.48][H.sub.40]
  x [H.sub.2]O               [N.sub.8][O.sub.5]Co
Ni[L.sup.1.sub.2]   Green    [C.sub.48][H.sub.40]
  x [H.sub.2]O               [N.sub.8][O.sub.5 Ni
Cu[L.sup.1.sub.2]   Green    [C.sub.46][H.sub.40]
  x [H.sub.2]O               [N.sub.8][O.sub.5]Cu

Compound            Yield   Elemental analysis % found (calculated)

                            C         H        N         M
[HL.sup.1]          85      72.68     5.21     14.28     -
                            (72.73)   (5.05)   (14.14)
Co[L.sup.1.sub.2]   70      66.34     4.98     12.99     6.35
  x [H.sub.2]O              (66.43)   (4.65)   (12.92)   (6.79)
Ni[L.sup.1.sub.2]   67      66.78     4.81     13.02     6.60
  x [H.sub.2]O              (66.45)   (4.65)   (12.92)   (6.76)
Cu[L.sup.1.sub.2]   60      65.61     5.15     13.41     7.63
  x [H.sub.2]O              (66.08)   (4.62)   (12.85)   (7.33)

Compound            [[mu].sub.eff]   [[lambda].sub.M]   Melting
                    B.M              [ohm.sup.-1]       Point
                                     [cm.sup.2]         [degrees]C

[HL.sup.1]          -                -                  196

Co[L.sup.1.sub.2]   4.93             11.56              286
  x [H.sub.2]O
Ni[L.sup.1.sub.2]   2.94             12.50              272
  x [H.sub.2]O
Cu[L.sup.1.sub.2]   1.90             10.34              260
  x [H.sub.2]O

TABLE 4: Relevant IR absorption bands for the ligand and metal

Compound                [nu]O-H   [nu]N-H   [nu]C=O   [nu]C=O
                                            (a)       (b)

[L.sup.1]               -         3132      1645      1596
Cu[([L.sup.1]).sub.2]   3448      3311      1597      -
  x [H.sub.2]O
Ni[([L.sup.1]).sub.2]   3376      3059      1621      -
  x [H.sub.2]O
Co[([L.sup.1]).sub.2]   3468      3275      1623      -
  x [H.sub.2]O

Compound                [nu]C=N   [nu]N-N   [nu]C-O   [nu]M-O

[L.sup.1]               -         1117      -         -
Cu[([L.sup.1]).sub.2]   1567      1026      1440      519
  x [H.sub.2]O
Ni[([L.sup.1]).sub.2]   1570      1027      1437      509
  x [H.sub.2]O
Co[([L.sup.1]).sub.2]   1566      1025      1438      510
  x [H.sub.2]O

Compound                [nu]M-N

[L.sup.1]               -
Cu[([L.sup.1]).sub.2]   418
  x [H.sub.2]O
Ni[([L.sup.1]).sub.2]   460
  x [H.sub.2]O
Co[([L.sup.1]).sub.2]   472
  x [H.sub.2]O

(a) Hydrazide moiety, (b) pyrazolone ring.

TABLE 5: Electronic spectra data ofligand and metal complexes.

Compounds           Bands ([cm.sup.-1])   Assigned transition

                    42,533 (10600)        n [right arrow] [[pi].sup.*]
[HL.sup.1]          32,786 (7500)         n [right arrow] [[pi].sup.*]
                    29,411 (9100)         n [right arrow] [[pi].sup.*]
                    21,276 (228)          [sup.4][T.sub.1g](F)
                                          [right arrow] [sup.4]
Co[L.sup.1.sub.2]   20,408 (224)          [sup.4][T.sub.1g](F)
                                          [right arrow]
  x [H.sub.2]O      10,204 (165)          [sup.4][T.sub.1g](F)
                                          [right arrow]
                    13,424(255)           [sup.2][B.sub.1g]
                                          [right arrow]
Cu[L.sup.1.sub.2]   16,354(135)           [sup.2][B.sub.1g]
                                          [right arrow]
  x [H.sub.2]O      22,722 (245)          [sup.2][B.sub.1g]
                                          [right arrow] [sup.2]Eg
                    23,809 (225)          [sup.3][A.sub.2g]
                                          [right arrow]
Ni[L.sup.1.sub.2]   14,174 (172)          [sup.3][A.sub.2g]
                                          [right arrow]
  x [H.sup.2]O      12,545 (142)          [sup.3][A.sub.2g]
                                          [right arrow]

TABLE 6: Antimicrobial activities of [HL.sup.1] and the metal
complexes (inhibition zone diameter (mm).

Test microorganism    [HL.     Co[L.sup.1.   Ni[L.sup.1.   Cu[L.sup.1.
                      sup.1]   sub.2] x      sub.2] x      sub.2] x
                               [H.sub.2]O    [H.sub.2]O    [H.sub.2]O

Escherichia coli      -        -             -             -
ATCC 25922
Salmonella            -        -             -             -
ATCC 14028
Micrococcus luteus,   15       -             -             12
ATCC 9341
Staphylococcus        15       -             -             14
ATCC 25923
Staphylococcus        -        -             -             -
ATCC 12228
Bacillus cereus       15       13            -             10
ATCC 11778
Bacillus subtilis     13       8             -             -
ATCC 6633
Bacillus              -        -             -             -
thuringiensis *
Enterococcus          -        -             -             -
ATCC 29212
Enterococcus          -        -             -             -
ATCC 51299
Streptococcus         -        -             -             -
ATCC 49617
Proteus sp.*          -        -             -             -
Serratia              -        -             -             -
marcescens *
Enterobacter sp. *    -        -             -             -
Listeria              -        -             -             -
monocytogenes **
Candida albicans      -        -             -             -
ATCC 90028
Candida utilis *      -        -             -             -
Candida               -        -             -             -
tropicalis *
Candida glabrata *    -        -             -             -
Saccharomyces         -        -             -             -
ATCC 9763

(-): zone of inhibition not included in the diameter of the well.

* Special gift from Faculty of Medicine, Adnan Menderes University.
** Food isolated.

TABLE 7: Minimum inhibitory concentration of compounds (MIC,
[mu]g x [mL.sup.-1]).

Test microorganisms     [HL.sup.1]   Co[L.sup.    Cu[L.sup.    Str
                                     1.sub.2] x   1.sub.2] x
                                     [H.sub.2]O   [H.sub.2]O

Micrococcus luteus,     4            NT           16           32
ATCC 9341
Staphylococcus aureus   4            NT           4            32
ATCC 25923
Bacillus cereus         4            4            64           64
ATCC 11778
Bacillus subtilis       8            128          NT           64
ATCC 6633

Note: Str: streptomycin.
(NT): Not tested.

TABLE 8: Antiproliferative activities of investigated compounds
against human cancer (HL-60) cell line.

Compounds     [HL.sup.1]   Co[L.sup.1   Ni[L.sup.1   Cu[L.sup.1
                           .sub.2] x    .sub.2] x    .sub.2] x
                           [H.sub.2]O   [H.sub.2]O   [H.sub.2]O

[IC.sub.50]   3.36 [+      2.52 [+      2.66 [+      4.20 [+
([micro]M)    or -] 1.12   or -] 0.22   or -] 0.54   or -] 1.44
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Asegbeloyin, Jonnie N.; Ujam, Oguejiofo T.; Okafor, Emmanuel C.; Babahan, Ilknur; Coban, Esin Poyraz
Publication:Bioinorganic Chemistry and Applications
Article Type:Report
Date:Jan 1, 2014
Previous Article:Synthesis, spectroscopic, molecular structure, and antibacterial studies of dibutyltin(IV) schiff base complexes derived from phenylalanine,...
Next Article:Degradation of methylene blue using biologically synthesized silver nanoparticles.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |